U.S. Banks Stock News

NYSE:JBS
NYSE:JBSFood

Assessing JBS (NYSE:JBS) Valuation After Recent Share Price Momentum And Earnings Stability

With no single headline event driving attention today, JBS (NYSE:JBS) is drawing interest as investors look at its recent share moves and its sizeable global meat processing footprint across beef, pork, poultry, and prepared foods. See our latest analysis for JBS. JBS’s recent 7 day share price return of 13.01% and 90 day share price return of 17.53%, with the stock now at $17.03, suggest momentum has picked up after a quieter 30 day share price return of 0.83%. If the JBS move has you...
NYSE:HE
NYSE:HEElectric Utilities

Hawaiian Electric Settlement Eases Legal Pressure But Leaves Court Risks

Hawaiian Electric Industries (NYSE:HE) has agreed to a $100 million settlement to resolve significant stockholder derivative lawsuits. The payment will be funded by insurers and also partially settles a related securities class action. The agreement is subject to final court approval, with upcoming hearings expected to clarify the remaining legal process. For shareholders watching NYSE:HE at a current share price of $14.67, this settlement addresses a key source of legal uncertainty. The...
NYSE:UNP
NYSE:UNPTransportation

Is Union Pacific (UNP) Offering Value After Its Recent 9.9% Share Price Pullback

Curious if Union Pacific at around US$238.79 is offering fair value or a margin of safety right now? This article walks through the key numbers that matter for you. The stock has seen mixed returns recently, with a 0.2% move over the last 7 days, a 9.9% decline over 30 days, gains of 3.0% year to date and 3.5% over the last year, and gains of 28.2% over 3 years and 19.6% over 5 years. Recent coverage of Union Pacific has focused on its role as a major U.S. railroad operator and how broader...
NasdaqGS:XEL
NasdaqGS:XELElectric Utilities

Xcel Energy Dam Safety Filings And What They May Mean For Investors

Xcel Energy (NasdaqGS:XEL) has filed new regulatory materials with the Federal Energy Regulatory Commission focused on dam safety and compliance. The company’s recent correspondence covers dam stability, embankment integrity, and landslide monitoring at its hydro-related facilities. These filings outline ongoing safety measures and responses to federal oversight of critical infrastructure. Xcel Energy, a regulated electric and natural gas utility, depends on reliable generation and...
NasdaqGS:SFD
NasdaqGS:SFDFood

Is It Too Late To Consider Smithfield Foods (SFD) After A 36.9% One Year Rally?

For readers wondering whether Smithfield Foods at US$26.69 still offers value, or if the easy gains are already behind it, this article breaks down what the current price might be implying. The stock has returned 13.7% over the past week, 7.3% over the last month, 20.5% year to date, and 36.9% over the past year, which naturally raises questions about how expectations and risk are now being priced in. Recent coverage around Smithfield Foods has focused on its positioning within the food...
NasdaqGS:VIAV
NasdaqGS:VIAVCommunications

Is It Too Late To Consider Viavi Solutions (VIAV) After A 210% One Year Surge?

If you are wondering whether Viavi Solutions at US$34.64 is still attractively priced after a big run, the key question is what that price actually reflects about the business. The stock has delivered returns of 3.1% over the past week, 16.6% over the past month, 90.9% year to date and 209.6% over the last year, with a 225.3% return over three years and 114.0% over five years, which puts recent valuation questions front and center. Recent coverage has focused on Viavi Solutions as a...
NasdaqCM:PVLA
NasdaqCM:PVLABiotechs

Palvella Hire Highlights QTORIN Launch Plans And Deep Rare Skin Focus

Palvella Therapeutics (NasdaqCM:PVLA) has appointed Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services. McDonough has extensive experience launching and commercializing therapies for rare skin diseases, including work on VYJUVEK®. The appointment is intended to support Palvella’s commercial readiness as QTORIN™ rapamycin advances through late-stage trials. For investors watching rare disease drug developers, Palvella Therapeutics sits at the intersection of...
NYSE:BBY
NYSE:BBYSpecialty Retail

Best Buy’s Dividend Hike And Earnings Beat Could Be A Game Changer For Best Buy (BBY)

In the past week, Best Buy reported quarterly results showing adjusted EPS of US$2.61, up 1.2% year over year, alongside a 0.8% decline in comparable sales and slightly softer-than-expected revenue, while also announcing a 1% increase in its quarterly dividend to US$0.96 per share. Management’s decision to raise the dividend and emphasize scalable profit drivers such as its digital Marketplace and Best Buy Ads highlights a focus on recurring, higher-margin revenue streams even as top-line...
NasdaqGS:PAYX
NasdaqGS:PAYXProfessional Services

Did Strong Q3 Results and Heavy Buybacks Just Reframe Paychex's (PAYX) Profitability Story?

In late March 2026, Paychex reported third-quarter revenue of US$1,808.9 million and net income of US$560.3 million, alongside updates on completing two share repurchase authorizations totaling US$400 million and US$352.22 million, and highlighted its cybersecurity focus ahead of an RSA Conference presentation. While revenue and quarterly earnings per share increased year over year, nine-month net income and EPS were slightly lower, underscoring that growth in sales has not yet translated...
NasdaqGS:CALM
NasdaqGS:CALMFood

Reassessing Cal-Maine Foods (CALM) After Recent Share Price Weakness

If you are wondering whether Cal-Maine Foods at around US$77.12 is pricing in too much optimism or leaving some value on the table, a closer look at its valuation can help frame that question. The share price is near US$77.12 after a 0.1% move over the last 7 days, with an 11.5% decline over 30 days, a 1.7% decline year to date, a 7.8% decline over 1 year, but a 53.8% gain over 3 years and a 159.0% gain over 5 years. Recent coverage has focused on Cal-Maine Foods as a key player in the US...
NasdaqGS:CDW
NasdaqGS:CDWElectronic

A Look At CDW (CDW) Valuation After Recent Share Price Weakness

CDW stock performance context CDW (CDW) has drawn attention after a period where the share price shows a 2.5% decline over the past day and negative returns over the week, month, past 3 months, year to date, and past year. See our latest analysis for CDW. At a share price of $118.17, CDW’s recent 1 day share price decline of 2.5% sits within a broader period of weaker momentum, with a 1 year total shareholder return of 25.0% in the red. This may reflect cooler sentiment around its risk and...
NasdaqGS:LULU
NasdaqGS:LULULuxury

Is It Time To Reassess Lululemon (LULU) After A 48% One Year Share Price Slide

If you are wondering whether lululemon athletica's current share price really reflects what the business is worth, starting with a clear look at valuation can help you frame that question properly. The stock last closed at US$145.85, with returns of an 11.3% decline over 7 days, a 21.2% decline over 30 days, a 30.8% decline year to date, and a 48.5% decline over the past year, which has likely shifted how many investors think about its potential and risk. Recent headlines around lululemon...
NasdaqGS:EA
NasdaqGS:EAEntertainment

Electronic Arts Buyout And AI Push Reshape Debt And Growth Outlook

Electronic Arts (NasdaqGS:EA) has completed a multi billion dollar private equity takeover, reshaping its ownership structure. JPMorgan Chase & Co. arranged complex financing to close the leveraged buyout in challenging market conditions. Management is highlighting plans to use artificial intelligence to drive the next phase of the company’s growth focus. For investors watching NasdaqGS:EA, the completed deal comes with the stock at $202.01 and a 1 year return of 40.4%. Over 3 years, the...
NYSE:CAH
NYSE:CAHHealthcare

Did Cardinal Health's (CAH) New Chair and Urology Deal Just Reframe Its Healthcare Partnership Strategy?

Cardinal Health recently announced that Patricia A. Hemingway Hall has succeeded Gregory B. Kenny as Chair of the Board following his retirement on March 23, 2026, after his long tenure guiding the company through portfolio changes and operational improvement efforts. Hemingway Hall’s elevation to Chair brings the perspective of a former health insurer CEO and long-serving governance leader at Cardinal Health, potentially shaping how the company approaches healthcare partnerships and...
NasdaqGS:SYBT
NasdaqGS:SYBTBanks

Assessing Stock Yards Bancorp (SYBT) Valuation As Mixed Signals Emerge From P/E And DCF Models

What stands out about Stock Yards Bancorp right now Stock Yards Bancorp (SYBT) has drawn attention after recent trading left the shares around $63.91, with returns showing small single digit moves over the past week, month, and past 3 months. See our latest analysis for Stock Yards Bancorp. While the 1 day share price return of 2.31% and year to date share price return of 1.98% are both negative, the 3 year total shareholder return of 24.86% and 5 year total shareholder return of 37.15%...
NasdaqGS:AMLX
NasdaqGS:AMLXPharmaceuticals

A Look At Amylyx Pharmaceuticals (AMLX) Valuation After LUCIDITY Phase 3 Trial Reaches Full Enrollment

Amylyx Pharmaceuticals (AMLX) drew fresh attention after announcing that the last participant in its pivotal Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia has been randomized and dosed, marking full enrollment. See our latest analysis for Amylyx Pharmaceuticals. With the shares recently at $13.55, Amylyx has a 1-day share price return of 0.59%, a 30-day share price decline of 10.68%, and a 1-year total shareholder return of 282.77%. The 3-year total shareholder return...
NasdaqGS:APEI
NasdaqGS:APEIConsumer Services

A Look At American Public Education (APEI) Valuation After Recent Share Price Momentum

Why American Public Education is on investors’ radar today American Public Education (APEI) is drawing attention after recent trading data highlighted strong momentum in its share price over the past month and past 3 months, prompting fresh interest in its fundamentals. See our latest analysis for American Public Education. At a share price of $57.24, American Public Education has seen strong recent momentum, with a 30 day share price return of 24.92% and a 1 year total shareholder return of...
NYSE:CVS
NYSE:CVSHealthcare

Is It Time To Revisit CVS Health (CVS) After The Recent Share Price Slump?

Wondering whether CVS Health at around US$70 still offers value, or if the easy money has already been made? This article walks through the key numbers so you can judge for yourself. The stock is around US$70.08 after a 1.7% decline over the past week and double digit declines of 12.3% for the past month and 12.5% year to date, even though the 1 year return sits at 7.4% and the 3 and 5 year returns are 3.4% and 10.0% respectively. Recent headlines around CVS Health have focused on its role...
NasdaqGS:WDC
NasdaqGS:WDCTech

Western Digital Explores Quantum Error Correction To Extend Data Reliability Story

Western Digital joined an open source quantum error correction initiative with Open Quantum Design and QuScript, targeting more reliable quantum computing. The collaboration focuses on setting shared standards and protocols for fault tolerant quantum systems. The move expands Western Digital's role beyond storage into quantum computing reliability and system level error correction. Western Digital (NasdaqGS:WDC) enters this partnership with a share price of $275.34 and very large 1 year and...
NYSE:BUR
NYSE:BURDiversified Financial

Burford Capital (BUR) Is Down 47.0% After YPF Ruling Triggers Major Case Write-Down Review

Burford Capital recently reported that the US Court of Appeals for the Second Circuit reversed the prior District Court judgment in favor of Petersen and Eton Park in the long-running YPF litigation, prompting the company to review the case’s carrying value and consider a potentially material asset write-down in its upcoming first-quarter results. This reversal directly affects a case that represents a large share of Burford’s fair value assets, underscoring how concentrated legal exposures...
NYSE:TWLO
NYSE:TWLOIT

Evaluating Twilio (TWLO) After Recent Share Price Weakness And Mixed Valuation Signals

Why Twilio is drawing investor attention now Recent trading in Twilio (TWLO) has brought its share performance back into focus for investors, as the stock reflects a mix of short term weakness and longer term gains across different time frames. See our latest analysis for Twilio. Recent weakness, including a 4.85% 1 day share price decline and a 16.75% 3 month share price retreat to US$119.99, contrasts with a 22.55% 1 year total shareholder return. This suggests momentum has cooled after...
NasdaqGS:VNET
NasdaqGS:VNETIT

VNET Group (VNET) Is Down 5.8% After Returning To Q4 Profitability With 2026 Revenue Guidance - Has The Bull Case Changed?

In March 2026, VNET Group, Inc. reported that fourth-quarter 2025 sales rose to CNY 2,687.09 million and net income reached CNY 304.67 million, reversing a net loss a year earlier, while full-year 2025 sales increased to CNY 9,949.26 million despite a net loss of CNY 251.84 million. The company also issued full-year 2026 guidance calling for total net revenues of RMB 11.5–11.8 billion, highlighting management’s confidence in sustaining double-digit growth in its data center business despite...
NYSE:BABA
NYSE:BABAMultiline Retail

Should Alibaba’s Shift to Huawei AI Chips Amid Profit Drop Require Action From Alibaba Group Holding (BABA) Investors?

Alibaba Group Holding Limited has already reported its third-quarter and nine-month results to December 31, 2025, showing modest sales growth but a sharp drop in net income and earnings per share versus the prior year. At the same time, Alibaba is preparing to adopt Huawei's new 950PR AI processor as US restrictions on Nvidia hardware push it toward domestically produced chips for its cloud and data center infrastructure. We’ll now examine how Alibaba’s shift toward Huawei’s 950PR AI chips...